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The MS-2 system (Abbott Diagnostics, Division of Abbott Laboratories, Dallas,
Tex.) was evaluated for its efficacy in determining the susceptibilities of both
clinical and selected challenge (nonfastidious, facultative, and aerobic) isolates.
The MS-2 results were compared with standard Kirby-Bauer disk diffusion and
microdilution results by using fresh clinical isolates. For gram-positive isolates
other than enterococci, overall agreement between MS-2 and reference results
was 93 to 98%. With enterococci, MS-2 agreement with disk diffusion was 68%
but with microdilution was 86% (agreement between disk diffusion and microdi-
lution was 73%). The main discrepancies with enterococci were with cephalothin,
penicillin, gentamicin, and kanamycin. With clinical gram-negative isolates, the
overall agreement was 91 to 93%, with most discrepancies occurring with Enter-
obacter spp. and ,B-lactam antibiotics (MS-2 versus disk diffusion, 84%; MS-2
versus microdilution, 84%; disk diffusion versus microdilution, 87%) and with
Serratia spp. and colistin (false-susceptible results). The agreement of MS-2
results with established reference antibiograms of a special collection of challenge
strains was 91 to 97% for the gram-positive cocci and 86 to 98% for the gram-
negative strains. (With Enterobacter spp., agreement was 86%, but was >90% for
all other organism groups.) Of the 98 finite MS-2 minimum inhibitory concentra-
tions (MICs) that could be directly compared with microdilution MICs, 77 (79%)
were within ±1 well of the geometric mean microdilution MIC. MS-2 analysis
time ranged from 2.8 to 6.5 h (mean, 4.2 h). On the basis of these results, we
conclude that the MS-2 can be expected to yield rapid and accurate results with
most nonfastidious, facultative, and aerobic pathogens.
Within the last decade, interest in developing
and using automated instrumentation in the
clinical microbiology laboratory has increased.
In most instances, such instrumentation has
been developed for antimicrobial susceptibility
testing (2, 5, 7). One recently developed system
is the MS-2 (Abbott Diagnostics, Division of
Abbott Laboratories, Dallas, Tex.). In the MS-2
system, a test organism is inoculated into a
cartridge with 11 cuvettes; 1 serves as an un-
treated growth control and the other 10 contain
antimicrobial agents. Growth is monitored tur-
bidimetrically at 5-min intervals, and suscepti-
bility is determined automatically by computer
comparison of growth kinetics in the presence of
an antimicrobial agent with kinetics in the un-
treated control, i.e., a comparison of growth
curves.
This is a report of a collaborative evaluation
of the MS-2 system. Performance of the system
was compared with that of two reference meth-
ods-the standardized agar disk diffusion and
the broth microdilution with both fresh clinical
isolates and a specific collection of organisms
selected to challenge the system with drug-or-
ganism combinations that are most important
clinically.
MATERIALS AND METHODS
Collaborative study. The collaborating investi-
gators (see Table 1, footnotes) developed a protocol
for evaluating the MS-2 system that was divided into
four phases. In phase 1, the investigators famiiarized
themselves with the MS-2 system and its operation
and checked all three methods by testing each of 18
selected organisms by each method. In phase Il, each
laboratory tested 200 fresh isolates obtained from its
own clinical specimens, selected to ensure that a pre-
determined number of each species was tested. The
actual distribution of organisms tested initially in
phase II is shown in Table 1.
In phase III, a special set of 179 challenge strains
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TABLE 1. Distribution of clinical isolates in phase
II testing
Organism CDC" Mayoh UNC' UW"
E. coli 54 45 40 43
Enterobacter spp. 23 23 23 21
Klebsiella spp. 20 20 20 20




P. mirabilis 18 18 18 18
Indole-positive Pro- 12 12 13 12
teus spp.
P. aeruginosa 22 21 20 20
Enterococci 14 15 8 15
Nonenterococcal 1 0 7 0
group D strepto-
cocci
S. aureus 27 24 22 25
S. epidermidis 12 il 12 12
Total 231 218 210 216
a CDC, Center for Disease Control, Atlanta, Ga.
h Mayo, The Mayo Clinic, Rochester, Minn.
'UNC, University of North Carolina, Chapel Hill.
UW, University of Washington, Seattle.
was selected by one of us (C.T.) to be tested in each of
the four laboratories. These challenge strains included
organisms that were both susceptible and multiply
resistant to a variety of clinically important antimicro-
bial agents. Isolates were deliberately selected without
regard to their normal frequency of clinical occurrence
to provide a severe test of the instrument. Numbers
were assigned to these organisms, and a blind-coded
set was sent to each of the four laboratories. Strains in
this collection were chosen so that the system would
be challenged with most of the known organism-anti-
biotic resistance patterns of clinical importance. Re-
sistance patterns of these organisms are summarized
in Tables 2 and 3. Any new susceptibility system
should be able to differentiate such resistant strains
from susceptible isolates of the same species.
Problem combinations encountered in the initial
phase Il and III studies were noted and corrected by
the manufacturer where possible. Such changes in-
cluded alterations in the cartridge design, alteration of
disk concentrations for ampicillin and kanamycin, and
modification of the analytic algorithm to improve the
accuracy of results on enterococci. Phase IV consisted
of repeat testing of the phase III challenge organisms
with such system improvements incorporated in the
MS-2. After phase IV, phase Il was repeated in two of
the four laboratories to confirm that the modification
system yielded acceptable results with the fresh clini-
cal isolates as well as with the challenge strains. (See
Tables 7 to 12 for data from these two laboratories.)
All organisms were tested with three methods: (i)
the MS-2 system, (ii) a standardized agar disk diffusion
method (4), and (iii) a broth microdilution method (6).
The same lots of media and antimicrobial agents were
used by all investigators. Inocula for the three tests
were prepared from several well-isolated colonies from
an overnight blood agar plate. For the MS-2 inoculum,
organisms were suspended directly in 4.0 ml of saline
to obtain a turbidity equivalent to a 0.5 McFarland
standard. The MS-2 cartridge was inoculated with an
appropriate volume of this saline suspension (see be-
low).
Organisms from the same colonies were, at the same
time, introduced into a tube of Trypticase soy broth
(BBL Microbiology Systems), which was incubated at
35°C until visible turbidity had developed (1 to 3 h).
Turbidity was adjusted to match the 0.5 McFarland
standard, and this suspension was used to inoculate
the agar disk diffusion plate. A further 1:10 dilution of
the Trypticase soy broth suspension was made for use
as the inoculum for the microdilution test.
MS-2 system. The MS-2 is an automated system
designed to perform antimicrobial susceptibility test-
ing by comparing growth kinetics of an organism in
the presence of an antimicrobial agent with growth
kinetics of an untreated control (5). Components of
the system (Fig. 1) include the cuvette cartridge, the
disk loader-sealer, a control module (computer), and
one or more analysis modules.
Antimicrobial agents for the MS-2 are supplied as
filter paper elution disks which are automatically dis-
pensed and sealed into the bottom of the appropriate
cuvette chambers by using the loader-sealer unit. Con-
tents of antimicrobial agents in the elution disks are
shown in Table 4. The cuvette cartridge has Il lower
chambers (cuvettes), one of which serves as a growth
control, with the other 10 each containing individual
antimicrobial agents. The upper part of the cartridge
is a chamber in which the culture grows into logarith-
mic phase before being automatically distributed into
TABLE 2. Resistance patterns ofgram-positive isolates tested in phases III and IV
No. of strains resistant to: No. of mul-
Organism (no. tested) tiresistant
Amp" Ceph Chlor Clind Eryth Gent Kana Meth Pen Tetra isolates
S. aureus (21) NTb O 6 5 il 0 4 2 16 7 13
S. epidermidis (21) NTb 1 2 7 8 5 10 7 15 5 il
Enterococci (16) 0 13 0 13 2 15 16 14 14 13 16
Other group D 0 0 0 0 0 0 4 2 2 3 4
streptococci (5)
Total (63) oc 14 8 25 21 20 34 25 47 28 44
a Amp, ampicillin; Ceph, cephalothin; Chlor, chloramphenicol; Clind, clindamycin; Eryth, erythromycin; Gent,
gentamicin; Kana, kanamycin; Meth, methicillin; Pen, penicillin; Tetra, tetracycline.
hAmpicillin not tested (NT) against staphylococci; see Pen data for f3-lactamase producers.
<Total of 21 isolates tested with ampicillin.
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TABLE 3. Resistance patterns ofgram-negative isolates tested in phases III and IV
No. of strains resistant to: No. of multi-
Organism (no. tested) resistant iso-
Amp" Carb Ceph Chlor Col Gent Kana Nitro Tetra lates
E. coli (21) 9 8 3 2 0 3 6 0 7 9
P. aeruginosa (29) 29 12 29 28 0 9 24 29 28 29
Proteus spp.' (22) 9 2 9 6 20 2 3 22 19 22
Enterobacter spp. (20) 18 5 19 3 3 1 3 4 3 20
Klebsiella pneumoniae 9 10 0 0 0 0 1 0 1 9
(10)
Serratia spp. (9) 6 1 8 2 9 1 2 8 5 9
Other' (5) 2 2 4 3 1 0 1 2 4 5
Total (116) 82 40 72 44 33 16 40 65 67 103
<Amp, ampicillin; Carb, carbenicillin; Ceph, cephalothin; Chlor, chloramphenicol; Col, colistin; Gent, genta-
micin; Kana, kanamycin; Nitro, nitrofurantoin; Tetra, tetracycline.
b P. mirabilis (14), P. vulgaris (4), P. rettgeri (3), and P. morganii (1). (The latter two species have been
reclassified since inception of this study.)
'Salmonella typhi (2), Shigella dysenteriae (1), Providencia stuartii (1), and Acinetobacter calcoaceticus
(1).
FIG. 1. The MS-2 system. From left to right are the control module, the analysis module, and the disk
loader-sealer. In the opening of the loader-sealer is a cuvette cartridge.
each of the 11 test cuvettes, i.e., before contact with
the antimicrobial agents. Only when the growing cul-
ture is distributed into the individual cuvettes are the
antibiotics eluted into the broth. Before the initiation
of this collaborative study, panels of drugs to be tested
with gram-positive cocci (staphylococci and strepto-
cocci) and with gram-negative bacilli had been se-
lected.
The computerized control module stores the infor-
mation entered by the operator concerning the test
organism (source, culture number, etc.), controls the
sequence of events leading to analysis, accesses and
stores the data, computes the evaluation of suscepti-
bility, and prints out the final report.
Each analysis module provides positions for eight
cartridges and contains individual electro-optical sys-
tems for monitoring turbidity within every cuvette in
each cartridge at 5-min intervals. Each module also
provides a constant temperature (35°C) and continual
agitation throughout the test. After the cartridge is
inserted into the analysis module, growth in the upper
chamber is monitored by the instrument at 5-min
intervals, and when the culture has shown a clear-cut
increase in optical density (change of at least 0.008),
indicating entry into logarithmic-phase growth, it is
automatically transferred into each of the 11 lower
cuvettes by the introduction of pulses of air pressure
into the upper growth chamber.
After the culture is transferred into the lower cu-
vettes, the antibiotics are eluted into the broth, and
the antibiotic action, if any, occurs. The turbidity in
each cuvette is read every 5 min, and all values are
stored in the computer memory.
As logarithmic growth proceeds, growth rate con-
stants are internally computed and verified, and rate
constants of the untreated control and growth curves
from each of the antimicrobial test chambers are com-
pared. Any antimicrobial agent causing a reduction of
growth rate to less than 10%o of the control value is
considered to be effective; i.e., the organism is suscep-
tible. In addition, a susceptible interpretation is as-
signed to any combination where clear-cut lysis of the
organism has occurred as defined by a progressive
negative rate constant (clearing of the bacterial sus-
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TABLE 4. Content of antimicrobial agents in elution
disks used in the MS-2 system
















" Two levels of carbenicillin were used in the MS-2:
a high range for P. aeruginosa and a low range for
other gram-negative bacilli.
h Pseudomonas spp. only.
' Ancillary studies were performed with disks con-
taining less of these antibiotics. Those results are
shown in Table 20.
" Units of penicillin.
pension). Conversely, organism-antimicrobial agent
combinations exhibiting a growth rate either similar
to or exceeding that of the untreated control are
designated as resistant.
The initial determination of rate constants occurs
during logarithmic-phase growth and is followed by a
second analysis, geared to the computed generation
time of the organism, which serves both to confirm the
initial analysis and to verify lytic activity or emergent
resistant growth. From these internally programmed
computer functions, susceptibility results are deter-
mined, and the antibiogram is automatically printed
out as a category (susceptible or resistant) or as a
minimal inhibitory concentration (MIC).
Results for each antimicrobial agent are printed as
follows: (i) susceptible ("S"), MIC less than a specific
concentration (e.g., <4 gg/ml); (ii) resistant ("R"),
MIC greater than a specific concentration (e.g., >12
ug/ml); or (iii) a finite computed intermediate ("1")
MIC (bounded by the two threshold concentrations in
i and ii above [e.g., 6.5 ,ig/ml]). These threshold values
are shown in Tables 5 and 6.
To perform a test with the MS-2 system, the appro-
priate battery of disks (Table 4) is loaded and sealed
into a cuvette cartridge, and 15 ml of modified (starch
omitted) Sensitest broth (Oxoid) is placed into the
upper chamber. Inoculum is prepared from an over-
night plate, as previously described, either 200,l (for
gram-negative organisms) or 400 id (for gram-positive
organisms) of the adjusted saline suspension is added
to the broth in the upper chamber, and the loading
port is sealed. After entering appropriate specimen
information via the computer keyboard, the operator
inserts the cuvette cartridge into its designated posi-
tion in the analysis module. This sequence is repeated
until all positions available in the analysis modules are
filled. The remaining functions in the test-incuba-
tion, agitation, turbidity readings, susceptibility deter-
minations, and repbrting-are all performed automat-
ically. Final analyses of different isolates occur at
different times, and as one culture is completed, an-
other cartridge can be inserted into that position with-
out waiting until all tests in that module are com-
pleted. For much of this study, two analysis modules
were used with a single control module.
Agar disk diffusion method. The standardized
agar disk diffusion tests were performed by the method
of Bauer et al. (1) as modified and described by the
National Committee for Clinical Laboratory Stand-
ards (4).
Broth microdilution method. Broth microdilu-
tion trays were prepared in each laboratory by using
a commercially available dispenser (MIC 2000; Dyna-
tech Laboratories). Each well of the trays was filled
with 0.1 ml of the Sensitest broth-antimicrobial agent
mixture. Filled trays were sealed in plastic bags and
stored at -70°C for a maximum of 2 weeks. They were
removed as needed, thawed, and inoculated with the
test organism using the MIC 2000 inoculator. The final
inoculum in each well was approximately 5 x 10"
colony-forming units per ml. Inoculated trays were
incubated for 18 to 24 h at 35°C before reading. The
MIC was the lowest concentration of drug that pre-
vented visibly detectable growth.
Interpretation of susceptibility results. The in-
terpretive criteria for the three methods used in this
study are shown in Tables 5 and 6. The breakpoints
for the disk diffusion zones were as described by the
National Committee for Clinical Laboratory Stand-
ards (4). Interpretive breakpoints for the microdilution
method were either those used previously (7) or were
decided jointly by the investigators in advance of the
study. Breakpoints for the MS-2 were programmed
into the instrument. Computed MICs within the range
bounded by the values shown were considered as
intermediate results. In some cases, the MS-2 pro-
gramming was designed to override an intermediate
result if specific biological events were detected, e.g.,
lysis or late-emergent outgrowth.
Three categories were established for comparing
the data from the MS-2 with those of the two reference
systems: discrepancies were categorized as minor (in-
volving an intermediate result), major (resistant by
MS-2 and susceptible by the reference method), or
very major (susceptible by MS-2 and resistant by the
reference method). For examination and resolution of
any discrepancies encountered during testing, growth
curves were generated from the recorded test data by
plotting optical density versus time (Fig. 2).
Reference antibiogram. With many of the orga-
nisms in the phase III challenge collection, disparate
results were obtained from the two standard reference
methods in one or more laboratories. Consequently, it
was deemed necessary to establish a reference antibio-
gram to serve as a fixed index for comparing accuracy.
All results obtained by disk diffusion and microdilution
in each of the four collaborating laboratories were
tabulated and reviewed to define the most probable
correct answer for each organism-antibiotic combina-
tion. Each combination was tested by disk diffusion
J. CLIN. MICROBIOL.
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TABLE 5. Interpretive criteria for disk diffusion, microdilution, and MS-2 tests with gram-positive
organisms
Kirby-Bauer disk diffusion zone Microdilution MIC (ig/ml) MS-2 MIC (Jlg/ml)
Drug diam (mm)
R" I S R I S R I S
Cephalothin C 14 15-17 '18 2 32 16 C8 -30 29.9-10.1 C10
Clindamycin C 14 15-16 ' 17 - 8 4 C2 - 3 2.9-1.1 C1
Erythromycin C 13 14-17 ' 18 - 8 4 C2 -9 8.9-3.1 C 3
Gentamicin C12 '13 216 8 C4 '12 11.9-4.1 C4
Methicillin c9 10-13 214 :16 8 C4 :15 14.9-5.1 C5
Penicillinb C 20 21-28 -29 >0.25 0.25 -6 5.9-2.1i 2
Penicillind <11 12-21 -22 -4 2 C1.0 -6 5.9-2.1 C2'
Tetracycline C14 15-18 219 '16 8 C4 '15 14.9-5.1 C5
Kanamycin 5 13 14-17 '18 - 32 16 C8 2 24 23.9-8.1 C 8
Chloramphenicol C 12 13-17 '18 - 32 16 C8 -27 26.9-9.1 S9
Ampicillin' c11 12-13 214 232 16 C8 27.5 7.4-2.6 C2.5
a R, resistant; I, intermediate; S, susceptible.
b Staphylococci.
c Units of penicillin.
d Streptococci.
e Enterococci only.
TABLE 6. Interpretive criteria for disk diffusion, microdilution, and MS-2 tests with gram-negative
organisms
Kirby-Bauer disk diffusion zone Microdilution MIC (,g/ml) MS-2 MIC (jig/ml)
Drug diam (mm)
R" I S R I S R I S
Ampicillin _11 12-13 214 232 16 C8 215 14.9-5.1 _5
Carbenicillinh C13 14-16 2:17 2256 128 S64 2300 299-101 _100
Carbenicillin' C17 18-22 223 264 32 _16 248 47.9-16.1 _16
Cephalothin C14 15-17 218 264 32 _16 230 29.9-10.1 l10
Chloramphenicol C12 13-17 218 232 16 S8 227 26.9-9.1 s9
Colistin C8 9-10 211 216 8 C4 218 17.9-6.1 S6
Gentamicin C12 213 216 8 _4 212 11.9-4.1 _4
Kanamycin _13 14-17 218 232 16 C8 224 23.9-8.1 C8
Nitrofurantoin C14 15-16 2-17 2128 64 C32 290 89.9-30.1 C30
Tetracycline C14 15-18 219 216 8 C4 215 14.9-5.1 C5
a See Table 5, footnote a.
b Pseudomonas spp.
' Other gram-negative organisms.
and microdilution at two different times in each of the III strains (phases III and IV testing). The reference
four laboratories, thereby yielding a total of 16 results antibiogram could not be used for phase Il strains,
for each combination. With these data, and without which were clinical isolates tested only in the labora-
consideration of results obtained -from the MS-2, a tory of origin.
reference antibiogram was established for most of the Antimicrobial agents, disks, and culture me-
more than 1,600 organism-antibiotic test combinations dia. Single lots of these materials were obtained and
in the phase III collection. In some cases, however, no distributed to each investigator to provide matched
clear-cut result was obtained from the multiple manual reagents in each of the laboratories. Disks and culture
testing. In these cases,' several of the investigators media used in the diffusion tests were obtained from
defined the most probable correct answer by scientific BBL Microbiology Systems.
and clinical judgment based on the relationship of
results of the test strain to those of sensitive members RESULTS
of the species, evidence for the presence of resistance As indicated above, the initial phase II and III
determinants, and experience with treatment of infec- studies revealed some problems in the MS-2tions due to similar organisms with the specific anti- stes ald somerems in the Ms
biotic. This antibiogram served as a reference against system, and changes were made to correct as
which the accuracy of any of the three test methods many as possible. For example, some computer
could be compared. It should be noted that this ref- software and analytical programs were changed,
erence base was available only for test results on phase the cuvette cartridge design was modified to
VOL. 12, 1980
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PLOT FREQUENCY 5 MINUTES
FIG. 2. MS-2-generated 4-h growth curves for a multiresistant strain of S. aureus. OD, optical density;
LGC, lower growth chamber; CNTL, control curve; I to 10, curves in 10 antimicrobial agents.
permit freer exchange of air, and the contents of
penicillin, methicillin, and clindamycin in elu-
tion disks were decreased.
After these system modifications, phase II
(clinical isolates) was repeated in two of the
collaborating laboratories. The efficacy of the
different-content elution disks was also verified
in two of the laboratories. Phase III strains
(challenge strains) were retested in four labora-
tories.
Phase H. In the initial phase Il studies (before
system modifications), correlations of MS-2 re-
sults with disk diffusion and microdilution for
the gram-positive cocci (Table 1) were 86.9 and
92.9%, respectively, and the correlations for
gram-negative organisms were 87.6 and 85.8%,
respectively.
The phase Il results obtained by the two
laboratories after system modifications are
shown in Tables 7 to 12. Agreement between
results of each method and the type of discrep-
ancy is tabulated by organism and antimicrobial
agent. In these tables, the numbers and types of
discrepancies are listed as very major, major, or
minor for the total number of organisms tested
(e.g., 0,3,0/25 means no very major, three major,
and no minor discrepancies for 25 organisms
tested).
Phase Il agreement between MS-2 and disk
diffusion results for the gram-positive cocci (Ta-
ble 7) was good for Staphylococcus aureus
overalll, 97.9%). Three reports of susceptibility
by the MS-2 and resistance by diffusion were
TABLE 7. Phase IL: MS-2 versus disk diffusion
results for gram-positive organisms"
No. of organismsh: Full
Drug agree-S. aureus S. epider- Entero- ment bymidis cocci drug (%)
Cephalothin 0,0,0/42 0,0,0/24 0,3,19/31 77.3
Clindamycin 0,0,0/42 0,0,0/24 3,0,0/31 96.9
Erythromycin 3,0,0/42 0,0,0/24 9,0,4/31 83.5
Gentamicin 0,0,0/42 0,4,0/24 0,16,0/31 79.4
Methicillin 0,0,0/42 0,0,5/24 0,0,0/31 94.8
Penicillin 3,0,1/42 4,0,2/24 0,1,28/31 59.8
Tetracycline 0,0,0/42 0,0,0/24 0,0,0/31 100.0
Kanamycin 0,0,1/42 0,0,0/24 1,0,12/31 85.6
Chloramphen- 0,0,0/42 0,0,0/24 0,0,1/31 99.0
icol
Ampicillin NT" NT 0,0,1/31 96.8
Full agree- 97.9 93.0 68.4 86.6"
ment by or-
ganism (%)
" The second method is the reference.h Numbers indicate very major, major, and minor discrep-
ancies, respectively, per total number of organisms. These
results were obtained in two laboratories, and thus the totals
do not agree with those in Table 1 (see the text).
NT, Not tested.
"Overall full agreement.
noted with penicillin. These were probably
weakly /B-lactamase-positive strains. Similarly,
very major errors with erythromycin were prob-
ably inducibly resistant strains. Lower accord
was observed between enterococci and genta-
micin, kanamycin, penicillin, cephalothin, and
erythromycin. With all of these combinations
except enterococci-erythromycin, the discrep-
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TABLE 8. Phase IL: MS-2 versus microdilution
results for gram-positive organisms"
No. of organismsh: Full
Drug ~~~~~~~~~~agree-Drug S. epider- Entero- ment by
S. aureus midis cocci drug (%)
Cephalothin 0,0,0/42 1,0,0/24 0,7,11/31 80.4
Clindamycin 0,0,0/42 0,0,0/24 1,0,1/31 97.9
Erythromycin 1,0,1/42 0,0,0/24 9,0,0/31 88.6
Gentamicin 0,0,0/42 0,2,0/24 1,0,8/31 88.6
Methicillin 0,0,0/42 0,0,3/24 0,0,0/31 96.9
Penicillin 2,2,0/42 2,1,0/24 1,3,0/31 88.6
Tetracycline 1,0,0/42 0,1,0/24 0,0,0/31 97.9
Kanamycin 0,0,1/42 0,0,0/24 1,0,0/31 97.9
Chloramphen- 0,0,0/42 0,0,0/24 0,0,0/31 100.0
icol
Ampicillin NT< NT 0,1,1/31 93.5
Full agree- 97.9 95.4 85.5 93.0'
ment by or-
ganism (%)
"h. '" See Table 7, footnotes a, b, c, and d.
TABLE 9. Phase Il: microdilution versus disk
diffusion results for gram-positive organisms"
No. of organisms': Full
Drug agree-S. aureus S. epider- Entero- meant bymidis cocci drug (%)
Cephalothin 0,0,0/42 0,1,0/24 2,1,12/31 83.5
Clindamycin 0,0,0/42 0,0,0/24 1,0,1/31 97.9
Erythromycin 1,0,1/42 0,0,0/24 0,0,4/31 93.8
Gentamicin 0,0,0/42 1,3,0/24 0,15,7/31 73.2
Methicillin 0,0,0/42 0,0,1/24 0,0,0/31 98.9
Penicillin 2,0,1/42 3,0,3/24 0,1,27/31 61.8
Tetracycline 0,1,0/42 1,0,0/24 0,0,0/31 97.9
Kanamycin 0,0,0/42 0,0,0/24 0,0,12/31 87.6
Chloramphen- 0,0,0/42 0,0,0/24 0,0,1/31 99.0
icol
Ampicillin NT NT 0,0,0/31 100.0
Full agree- 98.4 94.0 72.9 88.6'
ment by or-
ganism (%)
"h.̂ 'See Table 7, footnotes a, b, c, and d.
ancies were due to the high frequency of false-
susceptible or intermediate results obtained with
these drugs against enterococci in the disk dif-
fusion test when the MS-2 and microdilution
methods recorded them as resistant.
A comparison of MS-2 results with microdi-
lution data (Table 8) showed a much better
correlation for the enterococcus group, with
cephalothin and gentamicin discrepancies shift-
ing into the minor category, and a very substan-
tial (29%) increase in penicillin accord.
When results of disk diffusion were compared
directly with microdilution findings (Table 9), it
was apparent that substantial differences existed
between the two conventional reference meth-
ods with regard to susceptibility of enterococcal
isolates. Full accord between the two reference
methods for the enterococci was only 73%, show-
ing high levels of minor discrepancies with ceph-
alothin, penicillin, and kanamycin and a high
level of major discrepancies for gentamicin, ap-
parently due to false-susceptible results from the
disk diffusion method. As noted in Tables 5 and
6, disk diffusion breakpoints for gentamicin used
in these studies were from the first edition of the
National Committee for Clinical Laboratory
Standards (4) (recently a second edition has
been published containing different gentamicin
breakpoints); these may have contributed to the
level of discrepancies noted between the refer-
ence methods.
In summary, phase II MS-2 results with gram-
positive cocci showed a high level of full accord
with reference methods (93 to 98%) for the
staphylococci, but for enterococcal isolates, MS-
2 results compared more closely with microdi-
lution results than with those from the disk
diffusion method.
With the gram-negative phase II organisms, a
comparison of MS-2 versus disk diffusion results
(Table 10) showed excellent accord for Esche-
richia coli, Pseudomonas aeruginosa, Klebsi-
ella spp., Proteus mirabilis, and indole-positive
Proteus spp. Full accord was below 90% only for
Enterobacter isolates and other gram-negative
organisms, primarily Serratia isolates (Table 1).
Examination of the data showed that the very
major discrepancies with Enterobacter spp. oc-
curred specifically with ampicillin and cephalo-
thin, showing high agreement with all other
antimicrobial agents tested. Discrepancies in the
"other" category were mostly false-susceptible
results on Serratia spp. tested with colistin.
Aside from these three specific areas, other dis-
crepancies were primarily minor and were scat-
tered throughout the organism-antimicrobial
agent combinations.
Similar findings were observed in comparing
results of the MS-2 with microdilution (Table
11). Very major discrepancies with Enterobacter
spp.-ampicillin-cephalothin combination were
significantly reduced, whereas the Serratia spp.-
colistin results were unchanged. Full accord in
these areas remained below that obtained for ail
other organism groups. Except for ampicillin and
cephalothin, agreement for ail other antimicro-
bial agents was 90% or greater.
When disk diffusion results were compared
with those from microdilution (Table 12), ex-
actly the same problem areas as described above
were encountered, with the difference being that
very major discrepancies were several percent
lower and minor discrepancies were somewhat
higher. Overall full accord between the two ref-
erence methods (92.1%) was essentially identical
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TABLE 10. Phase IL: MS-2 versus disk diffusion results for gram-negative organisms
No. of organisms":
Other Full agree-Drug E P aerugi- Klebsiella P. mirab- Other Pro- Enterobac- gram-nega- ment by
E. Coli
nosa spp.lc.s teus spp.' ter spp. tive orga- drug
nisms'
Ampicillin 0,2,1/61 0,0,0/36 0,0,4/39 0,0,0/34 1,3,6/30 22,1,3/44 3,0,5/48 82.5
Carbenicillin 0,0,0/61 1,2,0/36 0,0,2/39 0,0,0/34 0,3,0/30 1,0,1/44 3,0,10/48 92.1
Cephalothin 0,1,8/61 1,0,0/36 1,0,1/39 0,1,0/34 0,1,0/30 14,1,5/44 1,0,2/48 87.3
Chloramphenicol 0,1,1/61 0,2,0/36 0,0,0/39 0,0,0/34 0,1,2/30 0,0,1/44 1,0,1/48 96.6
Gentamicin 0,1,3/61 0,0,0/36 0,0,0/39 0,0,0/34 0,0,0/30 0,1,0/44 0,1,1/48 97.6
Kanamycin 0,0,4/61 3,0,2/36 0,0,0/39 0,0,0/34 1,1,0/30 0,0,6/44 1,2,3/48 92.1
Colistin 0,0,0/61 0,0,0/36 0,0,0/39 0,0,0/34 0,0,1/30 0,0,0/44 11,1,2/48 94.9
Tetracycline 0,0,1/61 0,0,2/36 0,0,0/39 0,0,0/34 0,0,3/30 0,1,4/44 1,1,5/48 93.8
Tobramycin 0,4,0/61 1,0,2/36 0,0,0/39 0,0,0/34 0,1,0/30 0,0,1/44 0,0,5/48 95.2
Full agreement by
organism (91) 95.1 95.1 97.7 99.7 91.1 84.3 86.1 92.5'
See Table 7, footnote b.
h See Table 3, footnote b.
See Table 3, footnote c.
"'Overall full agreement.
TABLE 1 1. Phase IL: MS-2 versus microdilution results for gram-negative organisms
No. of organisms":
Other Fuît agree-Drug P. aerugi- Klebsiella P. mirab- Other Pro- Enterobac- gram-nega- ment by
E. Coli
nosa spp.lcs teus spp." ter spp. tive orga- drug (%)
nisms'
Ampicillin 0,1,0/61 0,0,0/35 1,0,2/39 0,0,0/35 1,2,4/31 14,1,5/44 4,1,10/48 84.3
Carbenicillin 0,0,2/61 2,2,2/35 2,0,0/39 0,0,0/35 0,3,0/31 0,0,1/44 4,1,10/48 90.1
Cephalothin 0,2,6/61 1,0,0/35 0,1,1/39 1,1,1/35 1,3,2/31 4,1,5/44 1,0,0/48 89.4
Chloramphenicol 1,0,3/61 0,0,1/35 0,0,0/39 1,0,4/35 0,0,4/31 0,0,3/44 5,0,4/48 91.1
Gentamicin 0,0,2/61 0,0,2/35 0,0,0/39 0,0,0/35 1,0,1/31 1,1,1/44 3,0,2/48 95.2
Kanamycin 0,1,3/61 3,0,2/35 0,0,0/39 0,0,2/35 1,1,0/31 3,0,3/44 2,2,1/48 91.8
Colistin 0,0,0/61 0,0,0/35 0,0,0/39 0,0,0/35 0,0,1/31 2,0,1/44 11,0,1/48 94.5
Tetracycline 0,0,2/61 0,0,2/35 0,0,0/39 0,0,1/35 0,0,0/31 4,0,6/44 2,1,5/48 92.2
Full agreement by 95.3 93.9 97.8 96.1 89.9 84.1 81.8 91.1<'
organism (91)
See Table 7, footnote b.
h See Table 3, footnote b.
<See Table 3, footnote c.
<'Overall full agreement.
to that obtained when MS-2 results were com-
pared with those of either method alone (92.5,
91.1%).
Phase IV results. Since phase IV results
were representative of MS-2 performance with
the phase III challenge strains after final system
improvements had been incorporated, only the
phase IV results will be considered in detail here.
In evaluating results obtained by the three
test methods in phase IV, we compared the
findings obtained by each method with those
obtained by the reference antibiogram since, as
previously noted, results produced by the two
conventional reference methods for many of
these strains were in conflict. Consequently, the
reference antibiogram was used as the reference
to compare the accuracy of each system.
MS-2 results for the challenge strains in the
Phase IV study are summarized in Tables 13
and 14. Accord between MS-2 results for gram-
positive organisms and the reference antibio-
gram is shown in Table 13. By organism group,
full accord with the MS-2 ranged from a low of
91.2% (for nonenterococcal group D strepto-
cocci) to 96.8% for S. aureus isolates. As a func-
tion of the specific antimicrobial agent tested,
results ranged from 91.4% with penicillin and
clindamycin to 100% for ampicillin. Overall full
accord for all combinations was 95.2%.
Similar data for the gram-negative organisms
studied in phase IV are shown in Table 14. As
previously described for the phase Il results,
very major discrepancies were noted with some
strains of Enterobacter and the fB-lactam anti-
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TABLE 12. Phase IL: microdilution versus disk diffusion results for gram-negative organisms"
No. of organisms:
Other Full agree-Drug E P aerugi- Klebsiella P. mirab- Other Pro- Enterobac- gram-nega- ment by
Coli nosa spp. LUs teus spp.' ter spp. tive orga- drug
nisms"
Ampicillin 0,0,0/61 0,0,0/35 0,1,4/39 0,0,0/35 0,2,9/31 5,0,3/44 0,1,12/48 87.4
Carbenicillin 0,0,2/61 0,1,2/35 0,0,2/39 0,0,0/35 0,0,0/31 0,0,0/44 3,3,4/48 94.2
Cephalothin 0,0,5/61 0,0,0/35 1,0,2/39 0,1,1/35 2,0,2/31 9,0,10/44 1,0,2/48 87.7
Chloramphenicol 0,2,2/61 0,0,1/35 0,0,0/39 0,1,5/35 0,0,4/31 0,1,2/44 0,5,5/48 90.4
Gentamicin 0,0,1/61 0,0,2/35 0,0,0/39 0,0,0/35 0,1,1/31 0,1,1/44 0,4,0/48 96.2
Kanamycin 1,0,3/61 0,0,4/35 0,0,0/39 0,0,3/35 0,0,0/31 0,1,4/44 1,3,4/48 91.8
Colistin 0,0,0/61 0,0,0/35 0,0,0/39 0,0,0/35 0,0,0/31 0,2,1/44 1,1,3/48 97.3
Tetracycline 0,0,2/61 0,0,2/35 0,0,0/39 0,0,0/35 0,0,3/31 0,4,2/44 0,1,9/48 92.1
Full agreement by 96.3 95.7 96.8 96.1 90.3 86.9 83.6 92.1`
organism (')
"The disk diffusion test is the reference.
See Table 7, footnote b.
See Table 3, footnote b.
"See Table 3, footnote c.
Overall full agreement.
TABLE 13. Phase IV: discrepancies between MS-2 and reference antibiogram results for gram-positive
organisms
No. of organisms<: Full agreement
Drug S. aureus S. epidermidis Enterococci Other by drug (%)
Ampicillin NTh NT 0,0,0/63 0,0,0/17 100.0
Cephalothin 0,1,0/83 1,0,0/80 0,0,0/63 0,0,0/17 99.2
Chloramphenicol 1,0,0/83 0,1,0/80 0,0,0/63 0,0/0/17 99.2
Clindamycin 0,0,0/83 4,0,0/80 17,0,0/63 0,0,0/17 91.4
Erythromycin 0,0,6/83 2,0,0/80 7,0,0/63 0,0,0/17 93.8
Gentamicin 0,0,0/83 1,0,0/80 2,1,1/63 0,2,2/17 96.3
Kanamycin 1,0,0/83 1,4,0/80 0,0,0/63 1,0,3/17 95.9
Methicillin 0,4,3/83 2,0,4/80 0,0,3/63 0,1,1/17 92.6
Penicillin 0,0,0/83 17,0,0/80 0,0,0/63 4,0,0/17 91.4
Tetracycline 7,0,1/83 2,0,0/80 0,0,0/63 0,0,1/17 95.5
Full agreement by 96.8 94.6 95.1 91.2 95.2`
organism (%)
" See Table 7, footnote b. The total number of organisms represents only those strains for which results were
obtained in all four laboratories and thus may not agree with the results in Table 1.
h NT, Not tested.
' Overall full agreement.
biotics and with Serratia spp. and colistin. Ex-
amining MS-2 growth curves showed that these
discrepancies resulted from late-emerging (de-
layed) resistance in these particular combina-
tions (this will be discussed later in more detail).
Full accord for the combinations noted above
was in the 86 to 88% range, but for all other
gram-negative organism groups and antibiotics
tested, full accord was found to be in the
range of 90 to 97%. Overall agreement for the
gram-negative organism-antibiotic combina-
tions tested was 92.4%.
In earlier stages of investigation of phase III
challenge organisms, several strains of S. aureus
selected for possession of inducible resistance to
erythromycin were found to yield susceptible
results in the MS-2 system. This problem had
previously been described in the Autobac I sys-
tem (8). Studies in the Abbott laboratories as-
certained that this problem could be effectively
resolved by adding subinhibitory levels of eryth-
romycin to the MS-2 medium before inoculating
the upper growth chamber. By adding inducer,
the problem of the major discrepancies with
these isolates was completely elninated (Table
15). The results for staphylococci shown in Table
13 (see also Table 17) were also obtained with
the use of erythromycin inducer.
A summary of the phase IV results is shown
in Table 16. The overall accuracy of the MS-2
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TABLE 14. Phase IV: discrepancies between MS-2 and reference antibiogram results for gram-negative
organisms
No. of organisms':
Other Full agree-Drug P. aerugi- Klebsiella Other Enterobac- gram-nega ment by drug
E. colu
ns
P. mira biis Proteus Eterospbac- gramnga-lo.sa spp. spp.^ te spp. tive org
nisms'
Ampicillin 0,8,0/80 1,0,0/112 0,4,0/40 0,0,1/48 0,1,2/38 26,2,2/79 1,5,6/60 87.1
Carbenicillin (low)" 0,0,0/80 1,0,1/40 0,0,0/48 0,5,1/38 4,4,1/79 1,4,0/60 93.6
Carbenicillin 5,5,5/112 86.5
(high)"
Cephalothin 0,6,0/80 0,0,1/112 0,0,0/40 0,0,0/48 0,0,3/38 26,0,1/79 2,0,0/60 91.5
Chloramphenicol 0,1,3/80 2,0,4/112 0,0,0/40 0,0,4/48 1,0,2/38 0,0,2/79 2,0,1/60 95.2
Colistin 0,1,0/80 0,0,2/112 0,0,1/40 0,0,0/48 2,1,4,38 3,0,1/79 31,0,0/60 90.0 (96.4)
Gentamycin 0,0,0/80 0,0,2/112 0,4,1/40 0,0,0/48 0,1,1/38 4,0,0/79 0,0,0/60 97.2
Kanamycin 0,7,0/80 6,1,8/112 0,0,1/40 0,0,0/48 0,1,0/38 0,0,1/79 0,0,0/60 94.5
Nitrofurantoin 0,0,0/80 1,0,3/112 0,2,9/40 2,0,1/48 0,0,5/38 0,4,17/79 0,0,1/60 89.5
Tetracycline 0,0,2/80 4,2,0/112 0,0,1/40 0,0,0/48 1,0,1/38 0,0,3/79 0,0,5/60 95.9
Full agreement by 96.1 94.8 93.0 98.2 90.7 86.0 89.1 (94.8)' 92.4" (93.3)'
organism (<i)
"See Table 7, footnote b.
"See Table 3, footnote b.
See Table 3, footnote c.
See Table 4, footnote a.
Value within parentheses indicates percent agreement if Serratia-colistin combination is removed from data base.
Overall full agreement.
TABLE 15. Effect of erythromycin inducer on MS-2
susceptibility results obtained with S. aureus and
erythromycin
No. of Discrepancies (%)Inducer"
stanstrains Very major Major Minor
No 84 26.1% 0 6%
Yes 83 0 0 7.2%
" 0.02 ig of erythromycin per ml of broth.
TABLE 16. Phase IV: overall full agreement of
three test methods versus the reference antibiogram
Agreement (c%)
Test method Gram-positive or- Gram-negative or-
ganisms ganisms
MS-2 95.2 92.4
Disk diffusion 91.0 96.8
Microdilution 96.2 94.4
system with gram-positive isolates was 95.2%
and with gram-negative organisms was 92.4%
when compared with the reference antibiogram.
Comparable values for the disk diffusion method
were 91.0 and 96.8%, respectively, and for the
microdilution method, 96.2 and 94.4%, respec-
tively.
MS-2 MIC results. As noted previously, the
MS-2 system produces susceptibility results in
both qualitative (resistant, intermediate, and
susceptible) and quantitative (MIC) modes.
To evaluate the accuracy of MICs obtained
from the MS-2, we compared them with MICs
from the microdilution method.
The "true" MIC was determined from the
eight microdilution endpoints obtained for each
organism-antibiotic combination in the four lab-
oratories. Agreement between the MS-2 and
microdilution MICs was defined as one of the
following categories: (i) the MS-2 MIC indicated
a susceptible threshold value (<X) and the mi-
crodilution endpoints were also less than X, e.g.,
MS-2 MIC <4 lig/ml and microdilution MIC =
2 ,ug/ml; (ii) the MS-2 MLU gave a resistant
threshold value (>Y) and microdilution values
were also greater than Y, e.g., MS-2 MIC >12
ig/ml and microdilution MIC = 16 ig/ml; or
(iii) the MS-2 results were finite computed
MICs, and the geometric mean (log2) of MS-2
values was within ±1.0 twofold increment of the
geometric mean of microdilution values (agree-
ment to within ± one well), e.g., MS-2 geometric
mean = 3.6 and microdilution geometric mean
= 4.1. Any set of data that failed to meet one of
the above criteria was considered to be in disa-
greement. These data are shown in Tables 17
(gram-positive cocci) and 18 (gram-negative ba-
cimi).
By organism, the overall MIC agreement
ranged from a low of 89% for Enterobacter spp.
to a high of 100% for the nonenterococcal group
D streptococci. By specific antibiotic, the overall
MIC agreement was greater than 90% for all
drugs except carbenicillin tested against P.
aeruginosa (82%) and penicillin (85%) when
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TABLE 17. Phase IV: agreement between MICs determined by MS-2 and microdilution for gram-positive
cocci
Agreement (%)
DrugNoetrccaS. aureus S. epidermidis Enterococci Nonenterococcal Overallgroup D streptococci
Ampicillin NT" NT 100 100 100
Cephalothin 100 100 93 100 98
Chloramphenicol 100 100 100 100 100
Clindamycinh 100 95 67 100 90
Erythromycin 100< 100 87 100 97
Gentamicin 100 100 100 100 100
Kanamycin 95 100 100 100 98
Methicillin 90 95 100 100 95
Penicillin G' 80 80 93 100 85
Tetracycline 100 100 100 100 100
Overall 96 97 94 100 96<"
" NT, Not tested.
h Original high level disks.
' Inducer added.
<Composite full agreement.
TABLE 18. Phase IV: agreement between MICs determined by MS-2 and microdilution for gram-negative
bacilli
Agreement (%)
Drug c Klebsiella Enterobac- Other p. aerugi-E. coli
SPP. ter spp.
P. mirabilis Proteus Posa Other" Overallspp ter sp« notsaspp.',
Ampicillin 95 100 63 100 100 100 93 92
Carbenicillin (low)' 100 100 89 100 75 93 94
Carbenicillin (high)' 82 82
Cephalothin 95 100 84 100 100 100 100 96
Chloramphenicol 100 100 100 92 100 93 93 96
Colistin 100 100 95 100 88 100 100 98
Gentamicin 100 90 95 100 100 96 100 97
Kanamycin 95 100 100 100 100 96 100 98
Nitrofurantoin 100 90 74 100 75 93 93 90
Tetracycline 100 100 100 100 100 93 100 98
Overall 98 98 89 99 93 95 97 95<'
«See Table 3, footnote b.
h See Table 3, footnote c.
'See Table 4, footnote a.
<'Composite full agreement.
tested with gram-positive cocci. Overall compos-
ite agreement of MICs for all phase IV organism-
antimicrobial agent combinations was 95 to 96%.
When individual organism-antimicrobial agent
combinations were examined, those showing
agreement of<90% were clindamycin and enter-
ococci (67%), erythromycin and enterococci
(87%), penicillin and S. aureus (80%), penicillin
and Staphylococcus epidermidis (80%), ampicil-
lin and Enterobacter spp. (63%), carbenicillin
and Enterobacter spp. (89%), carbenicillin and
other Proteus spp. (75%), carbenicillin and P.
aeruginosa (82%), cephalothin and Enterobac-
ter spp. (84%), nitrofurantoin and Enterobacter
spp. (74%), and nitrofurantoin and other Proteus
spp. (75%).
Since the great majority of strains tested
showed either clear-cut resistance or clear-cut
susceptibility to a given antimicrobial agent,
most of the MS-2 MIC results fell into categories
i or ii above, i.e., a comparison of threshold
values. Consequently, an additional specific
analysis was made of the category iii results, i.e.,
those in which finite MICs were computed by
the MS-2 for organism-antimicrobial agent com-
binations having intermediate levels of suscep-
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tibility. This occurred in less than 10% of the
combinations tested. For each such combina-
tion, the geometric mean (log2) of the four MS-
2 MICs was compared to the geometric mean of
eight microdilution MICs, and the level of agree-
ment to within ± one dilution was determined.
The results of this analysis are shown in Table
19. Most of the discrepancies noted were due to
intermediate MICs on resistant strains.
Improved disk concentrations. After com-
pleting phase IV, an additional ancillary study
was performed in two of the collaborative labo-
ratories (Center for Disease Control and the
University of Washington) to validate findings
by the manufacturer that reduced MS-2 disk
concentrations for penicillin, clindamycin, and
methicillin provided a substantial reduction in
discrepancies noted with gram-positive cocci
(Table 13). All gram-positive organisms in the
challenge collection were retested with the re-
duced disk concentrations, and the results are
summarized in Table 20. The data showed that
the 8% rate of very major discrepancies previ-
ously observed with penicillin and clindamycin
was reduced to less than 1% by use of the new
disk concentrations, and the high level of accord
with S. aureus was not affected.
Interlaboratory reproducibility. The level
of category agreement between participating
laboratories for all three susceptibility test pro-
cedures was examined and compared by using
phase IV results with the challenge strains (Ta-
ble 21). Total agreement, i.e., identical results in
all four laboratories, ranged from 83.6% (micro-
dilution with gram-negative bacilli) to 92.4%
(MS-2 with gram-positive cocci). When exam-
ined for agreement in three of four laboratories,
the values were substantially higher at 95% or
greater. Although there were slight differences
in the reproducibilities of the three methods,
these were not considered to be significant. We
concluded that reproducibility of results from
the MS-2 system was at least equal to that of
the reference methods when using lot-matched
reagents.
Analysis time. An analysis was made of ac-
tual time needed to obtain susceptibility results
with the MS-2 for all testing done in phase IV.
Since analysis time in the MS-2 system is a
function of biological growth rate rather than
clock time, a range of values was observed (Ta-
ble 22). The composite average test time for all
challenge strains in all four laboratories was 4.2
h.
DISCUSSION
The MS-2 has certain similarities to the
AutobacI system (7) in that tests are performed
in a cuvette cartridge having multiple individual
chambers, single concentrations of antimicrobial
agents are eluted into the broth from impreg-
nated paper disks, and tests are performed on
pure cultures in 3 to 6 h to obtain results on the
same day that susceptibility tests are initiated.
The MS-2 system differs in the method in
which these analyses are made. Growth (turbid-
ity) in each cuvette chamber is monitored at 5-
min intervals, and the data are stored in the
computer. From these data, growth curves are
generated by the computer for each organism-
drug combination and also for the organism in
the absence of antimicrobial agent (growth con-
trol).
The growth curves can be visually displayed
in research models of the MS-2 system, but in
the clinical instrument they are generated and
compared internally. After the susceptibility
analyses are made by the computer, the results
are automatically printed out. Isolates are cate-
gorized as susceptible if essentially complete in-
hibition or lysis has occurred and as resistant if
growth response approximates that of the un-
treated control. Between these qualitative
thresholds, MICs are automatically calculated
and reported.
Other differences are that organisms are per-
mitted to start growing before they are brought
into contact with the antimicrobial agents, and
the final susceptibility results are automatically
determined when adequate reaction between the
organism and the drugs has occurred.
In a previous collaborative study (7), an au-
tomated testing system was evaluated essen-
tially from data collected by using only recent
clinical isolates from within the United States.
As a consequence, certain important antibiotic-
organism resistance patterns were poorly repre-
sented because of their rarity in this country.
For that reason, we developed the set of selected
challenge strains (phase III strains) for the pres-
ent study. This collection was very useful both
to the manufacturer and to the evaluators in
defining potential problem areas with the new
system (e.g., the need for an erythromycin in-
ducer in tests with certain staphylococci). We
strongly recommend that a similar specific col-
lection of challenge organisms should be in-
cluded in any future evaluation of susceptibility
testing systems.
When discrepancies or other problems oc-
curred during testing, printed growth curves
from that test were referred to for clarification.
In each discrepancy situation, such growth
curves clearly indicated why the MS-2 made a
particular determination. This proved to be ex-
tremely useful in resolving discrepancies, cor-
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TABLE 19. Comparison ofMS-2 finite MICs with geometric mean microdilution MICs"
No. of MICs
Drug Organism
Total MS-2 Within Below Above









Carbenicillin Klebsiella spp. 1 1
Proteus spp. 2 1 1'
Enterobacter spp. 2 1 1'
Pseudomonas spp. 2 1 1Y
Cephalothin Enterobacter spp. 5 2 3h
Proteus spp. 1 1
S. epidermidis 1 1
Enterococci 2 2
Chloramphenicol E. coli 1 1
Proteus spp. 1 1
Acinetobacter spp. 1 1
Pseudomonas spp. 3 2 1'
S. epidermidis 1 1
Clindamycin S. epidermidis 1 ih
Colistin Proteus spp. 1ih
Enterobacter spp. 1 1'
Gentamicin Pseudomonas spp. 1 1h
Enterococci 6 6
Group D streptococci 3 3
Kanamycin Pseudomonas spp. 1 1
Group D streptococci 1 1
S. aureus 1 1ic
Methicillin S. epidermidis 6 5 1i
Nitrofurantoin Enterobacter spp. il il
Proteus spp. 7 6 1'
Pseudomonas spp. 2 2'
Klebsiella spp. 5 5
Penicillin S. epidermidis 6 6
S. aureus 2 2
Enterococci 2 2
Tetracycline Pseudomonas spp. 2 2
Serratia spp. 1 1
Totals 98 77 16 5
<'Total number of MS-2 MICs compared with microdilution MICs (geometric mean ± one well).
h>Intermediate MICs on resistant strains.
Intermediate MICs on susceptible strains.
" Five-tube or greater variance in microdilution MICs.
recting problem areas, and in understanding the those from disk diffusion showed a significant
actual kinetics of specific organism-antimicro- level of discrepancies when enterococci were
bial agent interactions. tested against penicillin, cephalothin, gentami-
Comparison of phase II MS-2 results with cin, and kanamycin (Table 7). The discrepancies
VOL. 12, 1980
388 THORNSBERRY ET AL.
TABLE 20. Ancillary study of lower content ofpenicillin, methicillin, and clindamycin disks: agreement of
MS-2 and reference antibiogram
.No.oforga-Disk concn (,ug) FullaccordI)DiscrepanciesNo.f DikcnenaMg) Fulla cord(%Organism or antibiotic no. of oranisma tested (%7)
New Old Very major Major Minor
Organism
S. aureus 42 96.7 1.6 0.3 1.4
S. epidermidis 40 97.2 1.3 0.8 0.7
Group D streptococci
Enterococcal 32 97.6 1.7 0.6 0.1
Nonenterococcal 8 94.4 0.7 1.4 3.5
Antibiotic
Clindamycin' 122 0.5 1.0 98.4 0.8 0 0.8
Methicillin" 122 4.0 5.0 94.3 0 2.4 3.3
PeniCi1in' 122 1.0h 2.0' 98.4 0.8 0 0.8
Overall accord 96.8 1.5 0.6 1.0
" Tested with organisms listed above.
h Units of penicillin.
TABLE 21. Interlaboratory reproducibility of the
three susceptibility methods with the phase III
challenge strains
No. of labora- Agreement (%,)
Organism tories in
agreement" MS-2 MTDh K-B'
Gram-positive 4 92.4 87.5 86.7
cocci 3 97.3 95.8 96.2
Gram-negative 4 87.1 83.6 90.1
bacilli 3 96.2 95.0 97.4
All organisms 4 88.9 85.0 88.9
(composite)" 3 96.6 95.3 97.0
" Total of four laboratories.
"MTD, Microdilution method.
K-B, Kirby-Bauer standardized disk diffusion method.
"'Total numbers of drug-organism combinations tested were
as follows: MS-2, 6,055; MTD, 6,000; K-B, 6,050.
observed with penicillin, cephalothin, and kan-
amycin were predominantly minor and due to
the large number of intermediate results by disk
diffusion. In the case of penicillin, this may have
been the result of interpreting zone diameters
for enterococci on the same basis as penicillin
and gram-negative bacilli (12 to 21 mm as inter-
mediate). The MS-2 usually recorded these
strains (with MICs of 4 to 8 ,g/ml) as resistant.
The aminoglycoside discrepancies were proba-
bly due to the known difficulty in performing
disk diffusion tests with these combinations.
Recommendations have been made that enter-
ococci not be tested with aminoglycosides by the
disk method (6). Phase Il agreement between





S. aureus 3.0-5.8 4.2




E. coli 2.9-5.3 3.8
P. aeruginosa 2.8-6.4 4.6
Enterobacter spp. 2.8-6.2 4.2
P. mirabilis 3.7-4.7 4.1
Indole-positive Proteus spp.<' 3.5-6.3 4.7
Klebsiella spp. 3.2-5.2 3.9
Other 3.3-6.4 4.5
Composite of all tests 4.2
"See Table 3, footnote b.
See Table 3, footnote c.
the two reference methods themselves (Table 9)
showed low accord for these same enterococci-
antimicrobial agent combinations, indicating
that estimations of accuracy depend heavily
upon which system is used as a reference.
For the gram-positive challenge strains (phase
IV testing), initial problems concerned the very
major discrepancies observed with penicillin and
clindamycin. The majority of penicillin discrep-
ancies occurred with strains of S. epidermidis
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FIG. 3. MS-2-generated 16-h growth curves for a strain of Enterobacter aerogenes. Curves 1 and 2 show
response to ampicillin (Amp) at 5 and 8 ug/ml, respectively; curve 3 is uith amoxicillin (Amox) at 8 gg/ml.
Note initial growth, subsequent lysis downwardd slope), and suppression, with emergence of resistant
outgrowth at 7 to 8 h. Other abbreviations are as in the legend to Fig. 2.
that produced low levels of 8B-lactamase. One
approach to resolving this problem was to reduce
the amount of antibiotic substrate, thus requir-
ing less enzyme for the resistance breakthrough.
This approach was highly successful (Table 20).
Reducing the clindamycin concentration in the
MS-2 disk also eliminated the discrepancies pre-
viously encountered with enterococci.
It should be reemphasized that diffusion tests
with enterococci and aminoglycosides yielded
inaccurate results and that these combinations
should not be tested routinely in the clinical
laboratory (6). Discrepancies in results obtained
by different methods when ,B-lactamase-nega-
tive organisms are tested with penicillin were
largely due to the definitions of the categories of
susceptibility that were used.
Problems encountered with gram-negative ba-
cilli were essentially limited to some strains of
Enterobacter and the ,B-lactam antibiotics am-
picillin and cephalothin. These discrepancies
were for the most part false-susceptible results.
Growth curves for such strains in the presence
of these drugs showed that within the normal 4-
to 6-h test period, growth, lysis, and complete
suppression had occurred, and the MS-2 had
correctly (for that time period) analyzed the
reaction as susceptible. However, subsequent
emergent resistant growth could be clearly ob-
served, occurring 8 to 14 h after antibiotic ex-
posure (Fig. 3). Recent studies of some of these
strains suggest that this resistant component
may represent emergence of low-level mutants
present in small numbers in the original suscep-
tible population (3). It is possible that in the
disk diffusion test some induction occurs and
that the use of Mueller-Hinton agar contributes
to the diffusion result. At present, no final solu-
tion has been defined for the Enterobacter spp.-
,B-lactam discrepancies, although preliminary
studies suggest that using a different cephalo-
sporin and penicillin may substantially decrease
this problem.
In the miscellaneous gram-negative organism
group designated "other," the great majority of
discrepancies occurred with Serratia spp. and
colistin (false-susceptible results). Of the very
major discrepancies seen with colistin, 79% oc-
curred with Serratia spp. This problem and this
combination is contraindicated for the MS-2
system. When Serratia and colistin results are
removed from the phase IV data, the very major
discrepancies with colistin are reduced from 7.6
to 1.8%, and the overall agreement with colistin
is 96.4%.
The microdilution MICs were determined in
modified Sensitest broth (Oxoid). Since the disk
diffusion test was the prime point of reference,
it was felt to be important to use the same
medium in the microdilution test as in the MS-
2 tests. However, microdilution tests in two lab-
oratories using the modified Sensitest broth and
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two lots of Mueller-Hinton (BBL Microbiology
Systems and Difco Laboratories) showed that
the MICs were essentially the same in both
media.
The MICs generated by the MS-2 differ from
the conventional MICs in at least two respects.
First, they are short-term MICs based upon
incubation times of 4 to 6 h, as opposed to 18 to
24 h. Second, MS-2 results are calculated from
a single concentration of drug as opposed to
conventional testing in which multiple concen-
trations are used. Although it was difficult to
directly compare microdilution MICs (the con-
centrations tested were a wide range of twofold
geometric progressions) with those obtained
from the MS-2 (limited-range continual concen-
trations in an arithmetic progression and thresh-
old values), when based upon the correlation
assumptions described earlier, the overall level
of agreement for all antibiotic-organism combi-
nations was 95% (Tables 17 and 18).
On the basis of these studies, the MS-2 system
can be expected to yield rapid, accurate, and
reproducible antimicrobial susceptibility results
with most of the nonfastidious, facultative, or
aerobic bacterial pathogens isolated from clini-
cal materials. The overall agreement compared
with defined susceptibility results (reference an-
tibiogram) for the set of phase IV challenge
strains was 96.8% for the gram-positive cocci and
92.4% for gram-negative organisms. The time
required to obtain test results in the MS-2 was
between 3 and 6 h. The efficacy of this system
for testing more fastidious organisms and anaer-
obic bacteria has not yet been determined.
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